Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (20)

2024

  1. Hospital pharmacy towards 2030

    Farmacia Hospitalaria, Vol. 48, pp. S52-S58

2023

  1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

  2. Agreement between pharmacists and physicians on the assessment of appropriateness of antimicrobial prescribing

    Enfermedades Infecciosas y Microbiologia Clinica

  3. Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. 155-160

  4. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  5. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review

    Pharmaceutics, Vol. 15, Núm. 3

  6. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA)

    Epilepsy and Behavior, Vol. 145

  7. [Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. T155-T160

2021

  1. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

    Infectious Diseases and Therapy, Vol. 10, Núm. 1, pp. 347-362

  2. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  3. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008-18

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

  3. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M

    Biomedicine and Pharmacotherapy, Vol. 121

  4. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Proposal of the SEOM, SEAP and SEFH for the creation of a National Strategy for Precision Medicine in Cancer

    Revista Espanola de Patologia

2017

  1. Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: A position statement of SEOM, SEAP and SEFH

    Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 688-691

2016

  1. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144

2012

  1. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7